Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Novacyt Gets CE Mark for Coronavirus Test

Novacyt Gets CE Mark for Coronavirus Test

Feb 18, 2020
|
staff reporter

NEW YORK – Novacyt said on Monday that its molecular test for the COVID-19 virus has received CE marking.

The company's molecular division, Primerdesign, has launched the test, which follows the launch of Novacyt's research-use-only coronavirus test on Jan. 31. Laboratories and hospitals can use the clinical test on patients without the need for validation by clinicians, according to Paris-based Novacyt.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. FDA Grants Emergency Use Authorization for University of Illinois Coronavirus PCR Test

  2. FDA Reissues EUA for Fluidigm SARS-CoV-2 Test for Use With Azova Home Collection Kit

  3. Mobidiag SARS-CoV-2, Influenza A/B, RSV Test Receives CE Mark

  4. Eurofins Scientific Posts 17 Percent Increase in FY2020 Revenues

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.